Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides-Reference-Cited by-同舟云学术

Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides

Published:2019-01 Issue:1 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wang Yiping¹,Mukhopadhyay Rupkatha¹,Roy Sujayita¹,Kapoor Arun¹,Su Yu-Pin¹,Charman Susan A.²,Chen Gong²,Wu Jianbo³,Wang Xiaofang³,Vennerstrom Jonathan L.³,Arav-Boger Ravit¹^ORCID

Affiliation:

1. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

2. Centre for Drug Candidate Optimization, Monash Institute of Pharmaceutical Sciences, Victoria, Australia

3. Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA

Abstract

Artesunate (AS), a semisynthetic artemisinin approved for malaria therapy, inhibits human cytomegalovirus (HCMV) replication in vitro , but therapeutic success in humans has been variable. We hypothesized that the short in vivo half-life of AS may contribute to the different treatment outcomes.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01735-18

Reference42 articles.

1. Seroprevalence of Cytomegalovirus Infection in the United States, 1988-1994

2. Betaherpesviruses in transplant recipients

3. Cytomegalovirus Infection and HIV-1 Disease Progression in Infants Born to HIV-1–Infected Women